Compare YMT & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YMT | CMND |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | China | Canada |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9M | 2.6M |
| IPO Year | 2023 | 2021 |
| Metric | YMT | CMND |
|---|---|---|
| Price | $0.22 | $1.82 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 849.5K | 138.5K |
| Earning Date | 06-09-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.12 | $0.07 |
| 52 Week High | $2.85 | $4.66 |
| Indicator | YMT | CMND |
|---|---|---|
| Relative Strength Index (RSI) | 30.99 | 51.33 |
| Support Level | $0.14 | $1.74 |
| Resistance Level | $0.35 | $2.25 |
| Average True Range (ATR) | 0.05 | 0.12 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 5.40 | 89.15 |
Yimutian Inc operates an agricultural B2B platform in China. It provides a comprehensive set of digital solutions to facilitate agricultural product transactions, ranging from searching and matching to transaction facilitation and settlement, through its Yimutian App and Douniu App. Additionally, leveraging its industry experience and market insights, the company has ventured into the realm of smart farming and agricultural sourcing and trading, further broadening its commercialization channels and animating its other business lines. The company operates as a single operating and reportable segment, as it offers a unified set of products and services mainly related to the provision of digital agricultural transaction services.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.